Skip to search formSkip to main contentSkip to account menu

BIIB021

Known as: BIIB-021 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

HSP90 inhibitor CNF2024

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors.
BACKGROUND HSP90 inhibition leads to proteosomal degradation of activated KIT and has in vitro activity against gastrointestinal… 
2013
2013
A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
Purpose: BIIB021 is the first oral, synthetic, non-geldanamycin–based HSP90 inhibitor that showed activity in preclinical models… 
2013
2013
A Purine Scaffold HSP90 Inhibitor BIIB021 Has Selective Activity against KSHV-Associated Primary Effusion Lymphoma and Blocks vFLIP K13-Induced NF-κB
Purpose: Kaposi sarcoma–associated herpes virus (KSHV)–associated primary effusion lymphomas (PEL) have extremely poor prognosis… 
Highly Cited
2009
Highly Cited
2009
BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90
Inhibition of heat shock protein 90 (Hsp90) results in the degradation of oncoproteins that drive malignant progression, inducing… 
Highly Cited
2009
Highly Cited
2009
CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy
Purpose: We designed and synthesized CUDC-305, an HSP90 inhibitor of the novel imidazopyridine class. Here, we report its unique… 
Highly Cited
2009
Highly Cited
2009
BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy
Heat shock protein 90 (Hsp90) is a molecular chaperone that promotes the conformational maturation of numerous client proteins… 
Highly Cited
2009
Highly Cited
2009
BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance
17‐AAG, the first‐generation clinical Hsp90 inhibitor, exhibits promising antitumor activity in clinical studies, but is limited… 
2009
2009
Heat Shock Protein 90 Inhibitor BIIB021 (CNF2024) Depletes NF-κB and Sensitizes Hodgkin's Lymphoma Cells for Natural Killer Cell–Mediated Cytotoxicity
Purpose: In Hodgkin's lymphoma, constitutive activation of NF-κB promotes tumor cell survival and proliferation. The molecular… 
Highly Cited
2009
Highly Cited
2009
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
Heat shock protein 90 (HSP90) inhibitors, such as 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin), which is… 
2008
2008
BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience
2503 Background: BIIB021 is an oral fully synthetic Hsp90 inhibitor that is being developed for both solid and hematologic tumors… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)